Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D29GPF
|
|||
| Drug Name |
DS-1211
|
|||
| Synonyms |
N-Acetyl-D-leucine; 19764-30-8; Ac-D-Leu-OH; D-leucine, N-acetyl-; N-Acetyl-R-leucine; (2R)-2-acetamido-4-methylpentanoic acid; Acetylleucine, D-; Acetylleucine, (R)-; (R)-2-acetamido-4-methylpentanoic acid; Leucine, N-acetyl-, D-; acetyl-d-leucine; 91WU82GA22; MFCD00066069; 2,N-Acetyl-D-leucine; D-acetylleucine; UNII-91WU82GA22; (R)-acetylleucine; N-acetyl-D-Leu; NCGC00094935-01; N-acetyl-(D)-leucine; SCHEMBL714003; CHEMBL174357; CHEBI:94479; DTXSID50361310; CHEBI:146296; WXNXCEHXYPACJF-SSDOTTSWSA-N; HY-Y1080; s4514; AKOS016842336; AKOS025117328; CCG-266380; CS-W020713; DS-1211; FD21901; NCGC00094935-02; AC-22376; A0713; AM20090137; A-1455; A20910; EN300-321381; Q-100200; BRD-K05831461-001-01-8; Z851793110
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Pseudoxanthoma elasticum [ICD-11: EC40] | Phase 2 | [1] | |
| Company |
Daiichi Sankyo Basking Ridge, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H15NO3
|
|||
| Canonical SMILES |
CC(C)CC(C(=O)O)NC(=O)C
|
|||
| InChI |
InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m1/s1
|
|||
| InChIKey |
WXNXCEHXYPACJF-SSDOTTSWSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alkaline phosphatase tissue-nonspecific (ALPL) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Folate biosynthesis | |||
| Metabolic pathways | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| Pathwhiz Pathway | Vitamin B6 Metabolism | |||
| WikiPathways | Endochondral Ossification | |||
| BDNF signaling pathway | ||||
| AGE/RAGE pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05569252) A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of DS-1211b in Individuals With PseudoXanthoma Elasticum. U.S.National Institutes of Health. | |||
| REF 2 | In Vitro and In Vivo Pharmacological Profiles of DS-1211, a Novel Potent, Selective, and Orally Bioavailable Tissue-Nonspecific Alkaline Phosphatase Inhibitor. J Bone Miner Res. 2022 Oct;37(10):2033-2043. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.